Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21231, USA.
J Nucl Med. 2011 Nov;52(11):1665-9. doi: 10.2967/jnumed.111.097733.
Chemokine receptor 4 (CXCR4)-chemokine ligand 12 (CXCL12) interactions have been shown to play key roles in cancer cell survival, proliferation, chemotaxis, homing, adhesion, tumor angiogenesis, and resistance to conventional and targeted therapies. Given its extensive involvement in cancer progression, the CXCR4-CXCL12 axis has been considered a therapeutic target. Several inhibitors blocking this signaling cascade are in phase I trials. Because CXCR4 is constitutively expressed in a wide variety of normal tissues, patient stratification and noninvasive monitoring would improve therapeutic outcome and reduce unnecessary toxicities. This review focuses on recent developments in CXCR4-based imaging agents and their potential role in the molecular diagnosis and treatment of cancer.
趋化因子受体 4（CXCR4）-趋化因子配体 12（CXCL12）相互作用已被证明在癌细胞存活、增殖、趋化性、归巢、黏附、肿瘤血管生成以及对常规和靶向治疗的耐药性中发挥关键作用。鉴于其在癌症进展中的广泛参与，CXCR4-CXCL12 轴已被视为治疗靶点。几种阻断这种信号级联的抑制剂正在进行 I 期临床试验。由于 CXCR4 在多种正常组织中持续表达，因此患者分层和非侵入性监测将改善治疗效果并减少不必要的毒性。本文重点介绍了基于 CXCR4 的成像剂的最新进展及其在癌症分子诊断和治疗中的潜在作用。
